Patents by Inventor Michael L. Dustin

Michael L. Dustin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for Using Protein Kinase C-Theta Inhibitors in Adoptive Immunotherapy
    Publication number: 20110142814
    Abstract: The present invention provides methods for reducing tumor necrosis factor activation of regulatory T cells (Tregs), restoring the activity of defective Tregs, and enhancing the function of Tregs using Protein Kinase C theta (PKC-?) inhibitors. The enhancement in Treg function is of use in facilitating adoptive immunotherapy in the treatment of immunological disorders.
    Type: Application
    Filed: December 15, 2010
    Publication date: June 16, 2011
    Applicant: New York University
    Inventors: Alexandra Zanin-Zhorov, Michael L. Dustin
  • Intercellular adhesion molecules and their binding ligands
    Publication number: 20090035321
    Abstract: The present invention relates to intercellular adhesion molecules (ICAM-1) which are involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, screening assays for identifying such molecules and antibodies capable of binding such molecules. The invention also includes uses for adhesion molecules and for the antibodies that are capable of binding them.
    Type: Application
    Filed: December 4, 2006
    Publication date: February 5, 2009
    Inventors: Timothy A. Springer, Robert Rothlein, Steven D. Marlin, Michael L. Dustin
  • Micropatterned T cell stimulation
    Publication number: 20080317724
    Abstract: The invention relates to methods of expanding, stimulating or activating T cells by modulating the spatial organization of signal molecules presented to the T cells.
    Type: Application
    Filed: January 18, 2008
    Publication date: December 25, 2008
    Inventors: Lance Kam, Keyue Shen, Michael L. Dustin, Vedra Kaye Thomas
  • Functional derivatives of ICAM-1 with altered ability to bind LFA-1 or HRV
    Patent number: 7354588
    Abstract: The present invention relates to intercellular adhesion molecules (ICAM-1) which are involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, screening assays for identifying such molecules and antibodies capable of binding such molecules. The invention also includes uses for adhesion molecules and for the antibodies that are capable of binding them.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 8, 2008
    Assignee: Dana Farber Cancer Institute
    Inventors: Timothy A. Springer, Robert Rothlein, Steven D. Marlin, Michael L. Dustin
  • Intercellular adhesion molecule—2 and its binding ligands
    Patent number: 6511664
    Abstract: The present invention relates to intercellular adhesion molecules (ICAM-2) which are involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, screening assays for identifying such molecules and antibodies capable of binding such molecules. The invention also includes uses for adhesion molecules and for the antibodies that are capable of binding them.
    Type: Grant
    Filed: February 13, 1996
    Date of Patent: January 28, 2003
    Assignee: Dana Farber Cancer Institute
    Inventors: Timothy A. Springer, Donald E. Staunton, Michael L. Dustin
  • ICAM-1 derivatives with altered ability to bind LFA-1
    Patent number: 6358510
    Abstract: The present invention relates to intercellular adhesion molecules (ICAM-1) which are involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, screening assays for identifying such molecules and antibodies capable of binding such molecules. The invention also includes uses for adhesion molecules and for the antibodies that are capable of binding them.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 19, 2002
    Assignee: Dana Farber Cancer Institute
    Inventors: Timothy A. Springer, Michael L. Dustin, Robert Rothlein, Steven D. Marlin
  • Soluble fragments of human intercellular adhesion molecule-1
    Patent number: 5831036
    Abstract: The present invention relates to intercellular adhesion molecules (ICAM-1) which are involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, screening assays for identifying such molecules and antibodies capable of binding such molecules. The invention also includes uses for adhesion molecules and for the antibodies that are capable of binding them.
    Type: Grant
    Filed: October 25, 1993
    Date of Patent: November 3, 1998
    Assignee: Dana Farber Cancer Institute
    Inventors: Timothy A. Springer, Robert Rothlein, Steven D. Marlin, Michael L. Dustin
  • Nucleotide sequence encoding intercellular adhesion molecule-1 and fragments thereof
    Patent number: 5612216
    Abstract: The present invention relates to intercellular adhesion molecules (ICAM-1) which are involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, screening assays for identifying such molecules and antibodies capable of binding such molecules. The invention also includes uses for adhesion molecules and for the antibodies that are capable of binding them.
    Type: Grant
    Filed: January 25, 1994
    Date of Patent: March 18, 1997
    Assignee: Dana Farber Cancer Institute
    Inventors: Timothy A. Springer, Robert Rothlein, Steven D. Marlin, Michael L. Dustin
  • Antibodies to ICAM-2, and fragments thereof
    Patent number: 5565550
    Abstract: The present invention relates to intercellular adhesion molecules (ICAM-2) which are involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, screening assays for identifying such molecules and antibodies capable of binding such molecules. The invention also includes uses for adhesion molecules and for the antibodies that are capable of binding them.
    Type: Grant
    Filed: February 10, 1994
    Date of Patent: October 15, 1996
    Assignee: Dana Farber Cancer Institute
    Inventors: Timothy A. Springer, Donald E. Staunton, Michael L. Dustin
  • Purified ICAM-2 and fragment thereof
    Patent number: 5512660
    Abstract: The present invention relates to intercellular adhesion molecules (ICAM-2) which are involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, screening assays for identifying such molecules and antibodies capable of binding such molecules. The invention also includes uses for adhesion molecules and for the antibodies that are capable of binding them.
    Type: Grant
    Filed: February 10, 1994
    Date of Patent: April 30, 1996
    Assignee: Dana Farber Cancer Institute, Inc.
    Inventors: Timothy A. Springer, Donald E. Staunton, Michael L. Dustin
  • Isolated nucleic acid molecules encoding ICAM-2
    Patent number: 5489533
    Abstract: The present invention relates to intercellular adhesion molecules (ICAM-2) which are involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, screening assays for identifying such molecules and antibodies capable of binding such molecules. The invention also includes uses for adhesion molecules and for the antibodies that are capable of binding them.
    Type: Grant
    Filed: February 6, 1995
    Date of Patent: February 6, 1996
    Assignee: Dana Farber Cancer Institute
    Inventors: Timothy A. Springer, Donald E. Staunton, Michael L. Dustin
  • R6-5-D6, an antibody which binds intercellular adhesion molecule-1
    Patent number: 5475091
    Abstract: The present invention relates to intercellular adhesion molecules (ICAM-1) which are involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, screening assays for identifying such molecules and antibodies capable of binding such molecules. The invention also includes uses for adhesion molecules and for the antibodies that are capable of binding them.
    Type: Grant
    Filed: January 25, 1994
    Date of Patent: December 12, 1995
    Assignee: The Dana Farber Cancer Institute
    Inventors: Timothy A. Springer, Robert Rothlein, Steven D. Marlin, Michael L. Dustin
  • Intercellular adhesion molecules, and their binding ligands
    Patent number: 5284931
    Abstract: Pharmaceutical compositions comprising antibodies to intercellular adhesion molecule-1 (ICAM-1 or CD54) are useful in methods of decreasing the severity of inflammation associated with the adhesion of leukocytes to cells bearing ICAM-1. Treatment with anti-ICAM-1 antibodies reduced the severity of inflammation associated with acute organ or tissue rejection and prolonged allograft survival time. Such compositions may optionally contain other immunsuppressive agents.
    Type: Grant
    Filed: April 27, 1990
    Date of Patent: February 8, 1994
    Assignee: Dana Farber Cancer Institute
    Inventors: Timothy A. Springer, Robert Rothlein, Steven D. Marlin, Michael L. Dustin
  • DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
    Patent number: 4956281
    Abstract: Polypeptides that bind to CD2, the receptor on the surface of T-lymphocytes. Most preferably, the polypeptides bind to CD2 on the surface of T-lymphocytes and inhibit adhesion between T-lymphocytes and target cells. DNA sequences that code on expression in appropriate unicellular hosts for those polypeptides. Methods of making and using those polypeptides in therapy and diagnosis.
    Type: Grant
    Filed: June 3, 1987
    Date of Patent: September 11, 1990
    Assignees: Biogen, Inc., Dana Farber Cancer Institute, Inc.
    Inventors: Barbara P. Wallner, Timothy A. Springer, Catherine Hession, Richard Tizard, Robert Mattaliano, Michael L. Dustin